Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Pomalid 1mg Tablets | 105-Count | POMALIDOMIDE
Oncology & Cancer CarePharma

Pomalid 1mg Tablets | 105-Count | POMALIDOMIDE

$250

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse POMALIDOMIDE — 1mg per tablet, 105-count pack. Third-generation IMiD for relapsed/refractory multiple myeloma after prior lenalidomide and proteasome inhibitor treatment, and AIDS-related Kaposi sarcoma. Key warning: TERATOGENIC — mandatory REMS. DVT/PE prophylaxis mandatory. CBC monitoring weekly. Dose reduction in renal impairment.

SKU
VES-005129-POMALID-1MG-105TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Pomalid 1mg (POMALIDOMIDE)?

Third-generation IMiD for relapsed/refractory multiple myeloma after prior lenalidomide and proteasome inhibitor treatment, and AIDS-related Kaposi sarcoma.

How it Works

Most potent IMiD — binds CRBN E3 ligase more potently than lenalidomide. Enhanced NK and T-cell immune activation against myeloma cells.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
POMALIDOMIDE
Dose per Tablet
1MG
Pack Size
105 tablets
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Profound myelosuppression (neutropenia), DVT/PE, fatigue, constipation, peripheral neuropathy, infections.

Safety Warnings

TERATOGENIC — mandatory REMS. DVT/PE prophylaxis mandatory. CBC monitoring weekly. Dose reduction in renal impairment. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.